Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis

Basit Öğe Kaydı
dc.contributor.authorŞimşek, Yavuz
dc.contributor.authorÇelik, Önder
dc.contributor.authorKaraer, Abdullah
dc.contributor.authorGül, Mehmet
dc.contributor.authorYılmaz, Ercan
dc.contributor.authorKoç, Önder
dc.contributor.authorAydın, Nasuhi Engin
dc.date.accessioned2020-04-30T23:34:39Z
dc.date.available2020-04-30T23:34:39Z
dc.date.issued2012
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionAydin, Nasuhi Engin/0000-0003-3145-2432;en_US
dc.descriptionWOS: 000307510200035en_US
dc.descriptionPubMed: 22648446en_US
dc.description.abstractThe current study investigated the potential therapeutic efficiency of atosiban, an oxytocin receptor antagonist, in an experimental endometriosis model. Endometriosis was surgically induced in 35 female rats during estrus. Four weeks after this procedure, relaparotomy was performed. The viability and dimensions of the endometriosis foci were recorded. Rats were then randomly divided into three groups. In the first group (n = 8), a daily dose of 0.2 ml 0.9 % NaCl was injected intraperitoneally (i.p.) (control cases). In the second and third groups (n = 8 and n = 8), 0.5 mg/kg/day i.p. atosiban and 1 mg/day i.p. diltiazem were given, respectively. At the end of the treatment, laparotomy was performed, and the dimensions of the endometriosis foci were recorded. The endometrial implants were processed for histological and immunohistochemical studies. The volumes of endometriotic implants were measured, and immunohistochemical analyses were performed, and compared between the groups. After the treatment with atosiban, volumes of endometriotic implants decreased significantly. Proliferating cell nuclear antigen expression levels were significantly reduced in the atosiban and diltiazem groups compared with the control group. In a rat endometriosis model, atosiban, an agent used for the first time for the medical treatment of endometriosis, has shown significant therapeutic efficiency.en_US
dc.identifier.doi10.1007/s00404-012-2390-7en_US
dc.identifier.endpage783en_US
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage777en_US
dc.identifier.urihttps://doi.org/10.1007/s00404-012-2390-7
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5201
dc.identifier.volume286en_US
dc.identifier.wosWOS:000307510200035en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofArchives Of Gynecology And Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometriosisen_US
dc.subjectReceptorsen_US
dc.subjectOxytocinen_US
dc.subjectAtosibanen_US
dc.subjectTherapyen_US
dc.titleTherapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5201.pdf
Boyut:
400.31 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu